New Yorkand GreenwoodVillage, Colo. (BusinessWire)-ANANDA Scientific Inc., a research focused bio-pharmaceutical company today announced that the first subject has been enrolled in the clinical trial with an FDA-approved IND evaluatingNantheia A1002N5S, an investigational drug using cannabidiol (CBD) inANANDA’sproprietary Liquid Structure delivery technology as a potential treatment forSocial Anxiety Disorder (SAD). The National Center for Complimentary and Integrative Health (NCCIH-a division of the NIH) is providing funding for this trial which is being conducted at theNYU Grossman School of Medicine. (Clinical Trials.gov Identifier:NCT05571592)The trial is being led by Principal InvestigatorsNaomi Simon, MD, MSc., Professor of Psychiatry and Director of Anxiety, Stress and Prolonged Grief Program at the NYU Grossman School of Medicine andEsther Blessing, MD, PhD, Assistant Professor of Psychiatry at NYU Grossman School of Medicine. This double-blind placebo-controlled trial is studyingNantheiaTMA1002N5Sversus placebo over a 21-day treatment period with the primary outcome measures being the change in Trier Social Stress Test (TSST) induced Anxiety and impact on a neuroimaging biomarker. “We are very pleased to have this important study underway,” saidDr. Simon. “Our collaboration with ANANDA is helping us complete our NIH funded research study of CBD, which is aimed at developing scientific evidence about its mechanism and clinical effects to support the potential development of CBD as a new evidence-based treatment for Social Anxiety Disorder, a distressing and under-addressed condition.” Dr. Blessing noted “preclinical results for CBD as a treatment for anxiety disorders show promising results and we look forward to building on these pre-clinical results in this study.” “Enrolling the first subject in this important trial is another key milestone for ANANDA’s clinical development program,” saidSohail R. Zaidi, ANANDA’s CEO. “We are very pleased to be collaborating with the NYU research team in evaluating our investigational drugNantheia A1002N5Sin an indication with a significant unmet medical need.” BOUT NANTHEIA A1002N5S Nantheia A1002N5Sis an investigational drug that uses cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure delivery technology (licensed fromLyotropic Delivery Systems (LDS) Ltdin Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol.Nantheia A1002N5Sis an oral product with 50mg cannabidiol per softgel capsule. BOUT ANANDA SCIENTIFIC NANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such asPTSD,Radiculopathic Pain,Anxietyand Opioid Use Disorder (Mt. SinaiandUCLA). The company employs patented delivery technology, (licensed fromLyotropic Delivery Systems (LDS) Ltd, in Jerusalem, Israel) to make cannabinoids and plant derived compounds bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio. Contacts NANDA Scientific Media Relations|Christopher Moore|813 326 4265|media@anandascientific.com Source: ANANDA Scientific Inc.
Source: Antara News Agency (ANA)